IDXX · Idexx Laboratories Inc /De · Executive Compensation
$521.12
+3.37 (+0.65%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$40.91B
Shares
78.78M
Volume · Oct 2
27.6K
Avg daily vol (3M)
567.06K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $14,580,122 |
| Michael J. Lane | Executive Vice President and General Manager, CAG Diagnostics Business Unit | $4,019,416 |
| Tina Hunt | Executive Vice President, Global Strategy and Commercial | $3,945,293 |
| Martin Smith | Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | $3,944,534 |
| Andrew Emerson | Executive Vice President and Chief Financial Officer | $3,033,071 |
| Brian McKeon | Former Executive Vice President, Chief Financial Officer and Treasurer | $351,680 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $13,007,051 |
| Brian McKeon | Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | $3,892,748 |
| Tina Hunt | Executive Vice President, Global Strategy and Commercial | $3,730,700 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | $3,726,323 |
| Martin Smith | Executive Vice President, Global Operations and R&D | $3,719,059 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $11,519,309 |
| Brian McKeon | Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | $3,845,065 |
| Tina Hunt | Executive Vice President, Global Strategy and Commercial | $3,570,793 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | $2,921,361 |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | $2,917,036 |
| Martin Smith | Executive Vice President, Global Operations and R&D | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $9,788,388 |
| Brian McKeon | Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | $3,510,826 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | $2,541,191 |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | $2,540,086 |
| Tina Hunt | Executive Vice President, Global Strategy and Commercial | $2,537,863 |
| Martin Smith | Executive Vice President, Global Operations and R&D | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $9,065,021 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $3,625,035 |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | $2,592,975 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | $2,592,658 |
| Tina Hunt | Executive Vice President, Strategy, Sector Development and Global Operations | $2,583,105 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $7,038,175 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $3,350,185 |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | $2,105,700 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | $1,909,005 |
| Sharon E. Underberg | Senior Vice President, General Counsel and Corporate Secretary | $1,881,117 |
| Tina Hunt | Executive Vice President, Strategy, Sector Development and Global Operations | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jonathan W. Ayers | Former Board Chair, President and Chief Executive Officer | $8,188,764 |
| Jonathan Mazelsky | President and Chief Executive Officer | $7,419,335 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $3,940,306 |
| Kathy V. Turner | Corporate Vice President and Chief Marketing Officer | $2,696,822 |
| Sharon E. Underberg | Senior Vice President, General Counsel and Corporate Secretary | $1,809,228 |
| Michael J. Lane | Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | $1,473,880 |
| Tina Hunt | Executive Vice President, and General Manager, Point of Care Diagnostics and Worldwide Operations | — |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Jonathan W. Ayers | Former Board Chair, President and Chief Executive Officer | $6,819,950 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $2,905,934 |
| Jonathan Mazelsky | President and Chief Executive Officer | $2,897,125 |
| Kathy V. Turner | Corporate Vice President and Chief Marketing Officer | $1,935,853 |
| Michael J. Lane | Executive Vice President and General Manager, Reference Laboratories and IT | $1,357,675 |
| Sharon E. Underberg | Senior Vice President, General Counsel and Corporate Secretary | — |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jonathan W. Ayers | Former Board Chair, President and Chief Executive Officer | $6,665,351 |
| Brian McKeon | Executive Vice President, Chief Financial Officer and Treasurer | $2,422,971 |
| Jonathan Mazelsky | President and Chief Executive Officer | $2,269,833 |
| Kathy V. Turner | Corporate Vice President and Chief Marketing Officer | — |
| Sharon E. Underberg | Corporate Vice President, General Counsel and Corporate Secretary | — |
| Michael J. Lane | Executive Vice President and General Manager, Reference Laboratories and Information Technology | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nimrata Hunt, PhD | Special Advisor | Appointed | 2026-03-26 |
| Nimrata Hunt, PhD | Executive Vice President, Global Strategy and Commercial | Terminated | 2026-03-26 |
| Michael (Mike) Erickson | Board of Directors | Appointed | 2026-01-13 |
| Michael (Mike) Erickson | President and Chief Executive Officer | Appointed | 2026-01-13 |
| Michael Erickson | President and Chief Executive Officer | Appointed | 2026-01-13 |
| Lawrence D. Kingsley | independent Lead Director | Appointed | 2026-01-13 |
| Michael (Mike) Erickson, PhD | Class II Director | Appointed | 2026-01-13 |
| Michael (Mike) Erickson, PhD | President and Chief Executive Officer | Appointed | 2026-01-13 |
| Jonathan (Jay) Mazelsky | Executive Chair of the Board | Appointed | 2026-01-13 |
| Karen Peacock | independent Class I Director | Appointed | 2025-10-07 |
| Joseph L. (Jay) Hooley | independent Class III Director | Appointed | 2025-07-10 |
| Dr. Asha Collins | Board of Directors | Resigned | 2025-02-14 |
| Andrew Emerson | Executive Vice President, Chief Financial Officer and Treasurer | Appointed | 2024-11-21 |
| Brian P. McKeon | Executive Vice President, Chief Financial Officer and Treasurer | Retired | 2024-11-21 |
| Jonathan W. Ayers | member of the Board of Directors | Resigned | 2024-11-12 |
| Asha S. Collins, PhD | Class I director | Appointed | 2024-05-10 |
| Sam Samad | Class I director | Appointed | 2024-05-10 |
| Bruce L. Claflin | Class I director | Appointed | 2024-05-10 |
| Irene Chang Britt | Class I director | Appointed | 2024-05-10 |
| James F. Polewaczyk | Executive Vice President | Retired | 2024-05-10 |
| James F. Polewaczyk | Executive Vice President and Chief Commercial Officer | Retired | 2023-12-07 |
| Irene Chang Britt | independent Class I Director | Appointed | 2023-07-12 |
Key facts
CIK
874716
CUSIP
45168D104
13F (30d)
23 filings
19 filers
Visit website
Investor relations